--- title: "Fulcrum Therapeutics (FULC) news: offering and merger" url: "https://aibio.space/companies/fulcrum-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "FULC offering and merger news: Fulcrum proposes $150.0 million stock offering, later upsized to $175.0 million. Fulcrum Therapeutics, Inc." --- FULC Fulcrum Therapeutics, Inc. NASDAQ · United States # Fulcrum Therapeutics (FULC) news FULC offering and merger news Mergers · 2026-08-17 ## [Fulcrum Therapeutics agrees to all-stock merger with Slate Medicines](https://aibio.space/news/fulcrum-therapeutics-agrees-all-stock-merger-slate-medicines/) Fulcrum's holders would own 5.0% of the combined company, after an estimated $270.0 million cash dividend paid before closing. The release reports no efficacy data for Slate's lead drug, whose first readout in mid-2027 covers safety and pharmacokinetics in healthy volunteers. ## Latest Fulcrum Therapeutics news 1. 2026-06-04 Distress [Fulcrum Therapeutics to cut workforce by approximately 85%, reviews strategic alternatives](https://aibio.space/news/fulcrum-therapeutics-cut-workforce-approximately-85-percent-reviews/) The restructuring follows the discontinuation of pociredir for sickle cell disease and carries expected charges of approximately $4.2 million. Leerink Partners LLC is advising the board. 2. 2026-06-01 Distress [Fulcrum Therapeutics drops pociredir and starts strategic review after FDA feedback](https://aibio.space/news/fulcrum-therapeutics-drops-pociredir-starts-strategic-review-after-fda/) Fulcrum ends pociredir, its lead sickle cell program, after FDA concerns about malignancy risk, and sets no timeline for its strategic review. It reported $333.3 million in cash, cash equivalents and marketable securities as of March 31, 2026. 3. 2025-12-08 Financings [Fulcrum proposes $150.0 million stock offering, later upsized to $175.0 million](https://aibio.space/news/fulcrum-proposes-150-0-million-stock-offering-later-upsized-175-0/) The $150.0 million offering priced on December 10, 2025 at $13.50 a share and was upsized to $175.0 million. Its lead drug data come from 12 patients in one dose cohort, and the dose comparison rests on six. ## Fulcrum Therapeutics at a glance - **Ticker**: FULC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $48.5 million ### Related companies - [Acrivon Therapeutics](https://aibio.space/companies/acrivon-therapeutics/) NASDAQ: ACRV - [Travere Therapeutics](https://aibio.space/companies/travere-therapeutics/) NASDAQ: TVTX - [Aytu BioPharma](https://aibio.space/companies/aytu-biopharma/) NASDAQ: AYTU - [Ocean Biomediacal](https://aibio.space/companies/ocean-biomediacal/) OTC: OCEA - [MediciNova](https://aibio.space/companies/medicinova/) NASDAQ: MNOV - [Skinvisible](https://aibio.space/companies/skinvisible/) OTC: SKVI - [Arcutis Biotherapeutics](https://aibio.space/companies/arcutis-biotherapeutics/) NASDAQ: ARQT - [Adicet Bio](https://aibio.space/companies/adicet-bio/) NASDAQ: ACET ### Also on NASDAQ - [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) COGT - [Rocket One](https://aibio.space/companies/rocket-one/) RKTO - [electroCore](https://aibio.space/companies/electrocore/) ECOR - [YD Bio](https://aibio.space/companies/yd-bio/) YDES - [Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) RARE - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) PCSA ## Fulcrum Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$56.1 million](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/) | [$63.4 million](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/) | | Net income (loss) | [-$74.9 million](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/) | [-$9.7 million](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/) | | Cash from operations | [-$60.1 million](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/) | [-$2.2 million](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/) | | Cash and equivalents | [$197.5 million](https://www.sec.gov/Archives/edgar/data/1680581/000119312526326098/) | [$58.2 million](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $48.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Fulcrum Therapeutics Has Fulcrum Therapeutics raised money recently? Our latest story on this, dated Dec 8, 2025: "Fulcrum proposes $150.0 million stock offering, later upsized to $175.0 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fulcrum-proposes-150-0-million-stock-offering-later-upsized-175-0/). Is Fulcrum Therapeutics involved in a merger or acquisition? Our latest story on this, dated Aug 17, 2026: "Fulcrum Therapeutics agrees to all-stock merger with Slate Medicines". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fulcrum-therapeutics-agrees-all-stock-merger-slate-medicines/). What is the ticker symbol of Fulcrum Therapeutics? Fulcrum Therapeutics, Inc. trades under the ticker FULC on NASDAQ. Where is Fulcrum Therapeutics listed? Fulcrum Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Fulcrum Therapeutics? The SEC Central Index Key (CIK) for Fulcrum Therapeutics, Inc. is 1680581. Its filings are on SEC EDGAR. How many shares does Fulcrum Therapeutics have outstanding? 76,297,257 shares as of 2026-07-23, per the cover page of its 10-Q filed 2026-07-30. Which country or territory is Fulcrum Therapeutics listed under? Our directory records Fulcrum Therapeutics, Inc. under United States. What does Fulcrum Therapeutics do? Our directory classifies Fulcrum Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Fulcrum Therapeutics? The ISIN recorded for Fulcrum Therapeutics, Inc. is US3596161097. Does aibio.space cover Fulcrum Therapeutics? aibio.space lists Fulcrum Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Fulcrum Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Fulcrum Therapeutics profitable? Fulcrum Therapeutics, Inc. reported a net loss of $74.9 million for the fiscal year ended Dec 31, 2025, and used $60.1 million of cash in operations, per its annual report to the SEC. How much does Fulcrum Therapeutics spend on research and development? $56.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Fulcrum Therapeutics have? $48.5 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Fulcrum Therapeutics (FULC) stock news? Our latest story on Fulcrum Therapeutics, dated Aug 17, 2026: "Fulcrum Therapeutics agrees to all-stock merger with Slate Medicines". Fulcrum's holders would own 5.0% of the combined company, after an estimated $270.0 million cash dividend paid before closing. The release reports no efficacy data for Slate's lead drug, whose first readout in mid-2027 covers safety and pharmacokinetics in healthy volunteers. [Source](https://aibio.space/news/fulcrum-therapeutics-agrees-all-stock-merger-slate-medicines/). ## Investor discussion: Fulcrum Therapeutics Members talk about Fulcrum Therapeutics (FULC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Fulcrum Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-17 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1680581/000119312526353278/d136791dex991.htm) 2. 2026-06-11 Distress Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 5.02). [Source](https://www.sec.gov/Archives/edgar/data/1680581/000119312526267659/fulc-20260605.htm) 3. 2026-06-01 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-ex99_1.htm) 4. 2026-04-27 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,2.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/fulc-ex99_1.htm) 5. 2025-12-08 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1680581/000119312525311359/d59184d424b5.htm) 6. 2025-07-29 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/fulc-ex99_1.htm) 7. 2025-03-04 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1680581/000095017025032355/fulc-20250226.htm) 8. 2024-12-23 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1680581/000119312524284214/d911298d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FULC on TradingView](https://www.tradingview.com/symbols/NASDAQ-FULC/). ## SEC filings and registration - **SEC name**: Fulcrum Therapeutics, Inc. - **CIK**: 1680581 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: FULC (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139 - **Phone**: 617-651-8851 - **Shares outstanding**: 76,297,257 as of 2026-07-23 (10-Q filed 2026-07-30) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1680581/000119312526353278/d136791d8k.htm) filed 2026-08-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1680581/000119312526341385/fulc-20260807.htm) filed 2026-08-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1680581/000119312526326098/fulc-20260630.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1680581/000119312526282873/d159102d8k.htm) filed 2026-06-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1680581/000119312526267659/fulc-20260605.htm) filed 2026-06-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/fulc-20260531.htm) filed 2026-06-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm) filed 2026-06-01 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1680581/000119312526197196/fulc-20260430.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001680581), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Fulcrum Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FULC, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Fulcrum Therapeutics, Inc. - **Ticker**: FULC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US3596161097 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FULC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/fulcrum-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Fulcrum Therapeutics (FULC) news: offering and merger", 2026-10-31, https://aibio.space/companies/fulcrum-therapeutics/